top of page

Checking in with Geron's CEO after imetelstat's recent ODAC meeting

John Scarlett shares his take on imetelstat's clinical utility, potential commercial dynamics, the IP situation, and more.



Comentarios


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page